Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendMost-Upgraded StocksMost-UpgradedNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $271.36 +4.68 (+1.75%) Closing price 10/7/2026 03:58 PM EasternExtended Trading$270.76 -0.60 (-0.22%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbbVie Stock (NYSE:ABBV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbbVie alerts:Sign Up Key Stats Today's Range$266.89▼$274.9450-Day Range$243.64▼$271.3752-Week Range$190.75▼$274.94Volume6.08 million shsAverage Volume4.37 million shsMarket Capitalization$479.44 billionP/E Ratio76.66Dividend Yield2.55%Price Target$274.32Consensus RatingModerate Buy Company Overview AbbVie Inc. is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health. The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care. AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories. Based in North Chicago, Illinois, the company serves patients and healthcare professionals in the United States and international markets. Robert A. Michael has served as AbbVie’s chief executive officer since July 2024.AI Generated. May Contain Errors. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreABBV MarketRank™: AbbVie scored higher than 85% of companies evaluated by MarketBeat, and ranked 87th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbbVie has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth15.72% Earnings GrowthEarnings for AbbVie are expected to grow by 15.72% in the coming year, from $13.93 to $16.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 76.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 76.66, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.56.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.22. PEG Ratios above 1 indicate that a company could be overvalued.Read more about AbbVie's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.10% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 4.48.Change versus previous monthShort interest in AbbVie has recently decreased by 0.10%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbVie pays a meaningful dividend of 2.59%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 42.93% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. News and Social Media4.1 / 5News Sentiment0.52 News SentimentAbbVie has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 75 news articles for AbbVie this week, compared to 8 articles on an average week.Search Interest78 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows91 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 78% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.Percentage Held by Insiders0.06% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Stock News HeadlinesWhy is AbbVie (ABBV) Stock Trending After Hours?October 7 at 11:11 PM | benzinga.comDow Jones Futures Fall As Yields Move Higher; Samsung, Micron, Taiwan Semi, Sandisk In FocusOctober 7 at 9:34 PM | finance.yahoo.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.October 8 at 1:00 AM | Golden Portfolio (Ad)Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer DrugOctober 7 at 4:33 PM | finance.yahoo.comAbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock UpOctober 7 at 11:32 AM | rttnews.comAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCOctober 7 at 11:32 AM | finance.yahoo.com3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note (ABBV)With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.October 3, 2026 | marketbeat.com3 Healthcare Dividend Stocks Offering More Than Just Income (ABBV)AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.September 30, 2026 | marketbeat.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $228.55 at the beginning of the year. Since then, ABBV stock has increased by 18.7% and is now trading at $271.3650. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, July, 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business's quarterly revenue was up 10.2% compared to the same quarter last year. Read the conference call transcript. Does AbbVie have any subsidiaries? AbbVie subsidiaries include Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more. Who are AbbVie's major shareholders? Top institutional shareholders of AbbVie include Ferguson Wellman Capital Management Inc. (0.04%), Eastern Bank (0.02%), MassMutual Private Wealth & Trust FSB (0.01%) and Violich Capital Management Inc. (0.01%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Perry C Siatis, Scott T Reents, Kevin K Buckbee and David Ryan Purdue. View institutional ownership trends. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC). Company Calendar Record date for 8/14 Dividend7/15/2026Ex-Dividend for 8/14 Dividend7/15/2026Last Earnings7/31/2026Dividend Payable8/14/2026Today10/07/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Next Earnings (Estimated)10/30/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ABBV's financial health is in the Green zone, according to TradeSmith. ABBV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees57,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$274.32 High Price Target$320.00 Low Price Target$225.00 Potential Upside/Downside+1.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$3.54 Trailing P/E Ratio76.66 Forward P/E Ratio19.48 P/E Growth1.22Net Income$4.23 billion Net Margins9.80% Pretax Margin13.51% Return on Equity-422.07% Return on Assets14.34% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69 Sales & Book Value Annual Sales$61.16 billion Price / Sales7.84 Cash Flow$15.41 per share Price / Cash Flow17.61 Book Value($1.83) per share Price / Book-148.29Miscellaneous Outstanding Shares1,766,790,000Free Float1,765,733,000Market Cap$479.44 billion OptionableOptionable Beta0.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:ABBV) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...International Living | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
